Fines of nearly €150 million imposed on pharmaceutical company Lundbeck and a number of generic rivals by the European Commission have been upheld by the EU General Court. The Court's decisions are the first to find that pay-for-delay agreements breach EU antitrust rules
Unlock this content.
The content you are trying to view is exclusive to our subscribers.
Rulings of note covered pre-June 2023 infringements and jurisdiction over non-UPC states, while winners of Managing IP’s EMEA Awards acted in multiple cases